nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—CYP3A4—prostate cancer	0.0841	1	CbGaD
Dabrafenib—SLCO1B3—Cabazitaxel—prostate cancer	0.0481	0.0859	CbGbCtD
Dabrafenib—SLCO1B3—Conjugated Estrogens—prostate cancer	0.0308	0.0549	CbGbCtD
Dabrafenib—SLCO1B1—Cabazitaxel—prostate cancer	0.028	0.05	CbGbCtD
Dabrafenib—SLCO1B1—Estrone—prostate cancer	0.0274	0.0489	CbGbCtD
Dabrafenib—SLCO1B3—Estradiol—prostate cancer	0.027	0.0482	CbGbCtD
Dabrafenib—ABCG2—Cabazitaxel—prostate cancer	0.0223	0.0397	CbGbCtD
Dabrafenib—ABCG2—Estrone—prostate cancer	0.0217	0.0388	CbGbCtD
Dabrafenib—CYP2C8—Nilutamide—prostate cancer	0.0193	0.0345	CbGbCtD
Dabrafenib—SLCO1B1—Conjugated Estrogens—prostate cancer	0.0179	0.032	CbGbCtD
Dabrafenib—SLC22A8—Conjugated Estrogens—prostate cancer	0.0165	0.0295	CbGbCtD
Dabrafenib—SLCO1B3—Docetaxel—prostate cancer	0.0161	0.0288	CbGbCtD
Dabrafenib—CYP2C8—Abiraterone—prostate cancer	0.016	0.0286	CbGbCtD
Dabrafenib—SLCO1B1—Estradiol—prostate cancer	0.0157	0.0281	CbGbCtD
Dabrafenib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0149	0.0267	CbGbCtD
Dabrafenib—SLC22A8—Estradiol—prostate cancer	0.0145	0.0259	CbGbCtD
Dabrafenib—ABCG2—Conjugated Estrogens—prostate cancer	0.0142	0.0254	CbGbCtD
Dabrafenib—ABCG2—Mitoxantrone—prostate cancer	0.0129	0.0231	CbGbCtD
Dabrafenib—ABCG2—Estradiol—prostate cancer	0.0125	0.0223	CbGbCtD
Dabrafenib—ABCB1—Estramustine—prostate cancer	0.0122	0.0217	CbGbCtD
Dabrafenib—CYP2C8—Cabazitaxel—prostate cancer	0.0119	0.0212	CbGbCtD
Dabrafenib—SLC22A6—Conjugated Estrogens—prostate cancer	0.0115	0.0206	CbGbCtD
Dabrafenib—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0103	0.0184	CbGbCtD
Dabrafenib—ABCG2—Etoposide—prostate cancer	0.00816	0.0146	CbGbCtD
Dabrafenib—ABCB1—Cabazitaxel—prostate cancer	0.00802	0.0143	CbGbCtD
Dabrafenib—CYP3A4—Bicalutamide—prostate cancer	0.00784	0.014	CbGbCtD
Dabrafenib—ABCB1—Estrone—prostate cancer	0.00784	0.014	CbGbCtD
Dabrafenib—ABCG2—Docetaxel—prostate cancer	0.00746	0.0133	CbGbCtD
Dabrafenib—CYP3A4—Estramustine—prostate cancer	0.00729	0.013	CbGbCtD
Dabrafenib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00699	0.0125	CbGbCtD
Dabrafenib—CYP2C8—Estradiol—prostate cancer	0.00665	0.0119	CbGbCtD
Dabrafenib—CYP3A4—Abiraterone—prostate cancer	0.0065	0.0116	CbGbCtD
Dabrafenib—CYP3A4—Flutamide—prostate cancer	0.0065	0.0116	CbGbCtD
Dabrafenib—NEK11—prostate gland—prostate cancer	0.00569	0.111	CbGeAlD
Dabrafenib—ABCG2—Doxorubicin—prostate cancer	0.00556	0.00993	CbGbCtD
Dabrafenib—ABCB1—Conjugated Estrogens—prostate cancer	0.00513	0.00916	CbGbCtD
Dabrafenib—CYP3A4—Cabazitaxel—prostate cancer	0.00481	0.00858	CbGbCtD
Dabrafenib—CYP3A4—Estrone—prostate cancer	0.0047	0.00839	CbGbCtD
Dabrafenib—ABCB1—Mitoxantrone—prostate cancer	0.00466	0.00833	CbGbCtD
Dabrafenib—ABCB1—Estradiol—prostate cancer	0.0045	0.00804	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—prostate cancer	0.00434	0.00776	CbGbCtD
Dabrafenib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00419	0.00748	CbGbCtD
Dabrafenib—LIMK1—prostate gland—prostate cancer	0.00407	0.0793	CbGeAlD
Dabrafenib—ABCB1—Prednisone—prostate cancer	0.00387	0.00692	CbGbCtD
Dabrafenib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00307	0.00549	CbGbCtD
Dabrafenib—ABCB1—Etoposide—prostate cancer	0.00294	0.00525	CbGbCtD
Dabrafenib—CYP3A4—Mitoxantrone—prostate cancer	0.00279	0.00499	CbGbCtD
Dabrafenib—SLC22A8—urine—prostate cancer	0.00271	0.0529	CbGeAlD
Dabrafenib—CYP3A4—Estradiol—prostate cancer	0.0027	0.00482	CbGbCtD
Dabrafenib—ABCB1—Docetaxel—prostate cancer	0.00269	0.00481	CbGbCtD
Dabrafenib—BRAF—prostate gland—prostate cancer	0.00251	0.049	CbGeAlD
Dabrafenib—NEK11—testis—prostate cancer	0.00251	0.0488	CbGeAlD
Dabrafenib—CYP3A4—Prednisone—prostate cancer	0.00232	0.00414	CbGbCtD
Dabrafenib—SIK1—prostate gland—prostate cancer	0.0021	0.041	CbGeAlD
Dabrafenib—ABCB1—Doxorubicin—prostate cancer	0.00201	0.00358	CbGbCtD
Dabrafenib—NEK11—lymph node—prostate cancer	0.00182	0.0354	CbGeAlD
Dabrafenib—LIMK1—testis—prostate cancer	0.00179	0.0349	CbGeAlD
Dabrafenib—CYP3A4—Etoposide—prostate cancer	0.00176	0.00315	CbGbCtD
Dabrafenib—RAF1—prostate gland—prostate cancer	0.00168	0.0326	CbGeAlD
Dabrafenib—CYP3A4—Docetaxel—prostate cancer	0.00161	0.00288	CbGbCtD
Dabrafenib—SIK1—renal system—prostate cancer	0.00143	0.0279	CbGeAlD
Dabrafenib—RAF1—seminal vesicle—prostate cancer	0.00142	0.0276	CbGeAlD
Dabrafenib—SIK1—urethra—prostate cancer	0.00141	0.0275	CbGeAlD
Dabrafenib—CYP3A4—urine—prostate cancer	0.00134	0.0262	CbGeAlD
Dabrafenib—LIMK1—lymph node—prostate cancer	0.0013	0.0253	CbGeAlD
Dabrafenib—BRAF—bone marrow—prostate cancer	0.0013	0.0252	CbGeAlD
Dabrafenib—RAF1—epithelium—prostate cancer	0.00123	0.024	CbGeAlD
Dabrafenib—CYP3A4—Doxorubicin—prostate cancer	0.0012	0.00215	CbGbCtD
Dabrafenib—RAF1—renal system—prostate cancer	0.00114	0.0222	CbGeAlD
Dabrafenib—RAF1—urethra—prostate cancer	0.00112	0.0218	CbGeAlD
Dabrafenib—BRAF—testis—prostate cancer	0.00111	0.0216	CbGeAlD
Dabrafenib—SIK1—bone marrow—prostate cancer	0.00108	0.0211	CbGeAlD
Dabrafenib—SLC22A8—prostate gland—prostate cancer	0.000974	0.019	CbGeAlD
Dabrafenib—SIK1—testis—prostate cancer	0.000927	0.0181	CbGeAlD
Dabrafenib—RAF1—bone marrow—prostate cancer	0.000863	0.0168	CbGeAlD
Dabrafenib—SLCO1B1—renal system—prostate cancer	0.000854	0.0166	CbGeAlD
Dabrafenib—BRAF—lymph node—prostate cancer	0.000803	0.0156	CbGeAlD
Dabrafenib—RAF1—testis—prostate cancer	0.000738	0.0144	CbGeAlD
Dabrafenib—ABCG2—prostate gland—prostate cancer	0.000693	0.0135	CbGeAlD
Dabrafenib—SIK1—lymph node—prostate cancer	0.000672	0.0131	CbGeAlD
Dabrafenib—SLC22A8—renal system—prostate cancer	0.000664	0.0129	CbGeAlD
Dabrafenib—ABCG2—seminal vesicle—prostate cancer	0.000586	0.0114	CbGeAlD
Dabrafenib—RAF1—lymph node—prostate cancer	0.000535	0.0104	CbGeAlD
Dabrafenib—CYP2C8—renal system—prostate cancer	0.000486	0.00946	CbGeAlD
Dabrafenib—ABCG2—urethra—prostate cancer	0.000464	0.00904	CbGeAlD
Dabrafenib—ABCG2—bone marrow—prostate cancer	0.000357	0.00696	CbGeAlD
Dabrafenib—ABCB1—prostate gland—prostate cancer	0.000342	0.00666	CbGeAlD
Dabrafenib—CYP3A4—renal system—prostate cancer	0.000329	0.00641	CbGeAlD
Dabrafenib—CYP2C8—testis—prostate cancer	0.000314	0.00612	CbGeAlD
Dabrafenib—ABCG2—testis—prostate cancer	0.000305	0.00595	CbGeAlD
Dabrafenib—ABCB1—seminal vesicle—prostate cancer	0.000289	0.00563	CbGeAlD
Dabrafenib—ABCB1—epithelium—prostate cancer	0.000251	0.00489	CbGeAlD
Dabrafenib—ABCB1—renal system—prostate cancer	0.000233	0.00454	CbGeAlD
Dabrafenib—ABCB1—urethra—prostate cancer	0.000229	0.00446	CbGeAlD
Dabrafenib—ABCG2—lymph node—prostate cancer	0.000221	0.00431	CbGeAlD
Dabrafenib—ABCB1—bone marrow—prostate cancer	0.000176	0.00343	CbGeAlD
Dabrafenib—ABCB1—testis—prostate cancer	0.000151	0.00293	CbGeAlD
Dabrafenib—ABCB1—lymph node—prostate cancer	0.000109	0.00213	CbGeAlD
Dabrafenib—Cough—Docetaxel—prostate cancer	5.05e-05	0.000304	CcSEcCtD
Dabrafenib—Hypersensitivity—Mitoxantrone—prostate cancer	5.03e-05	0.000303	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—prostate cancer	5.02e-05	0.000303	CcSEcCtD
Dabrafenib—Diarrhoea—Estradiol—prostate cancer	5.01e-05	0.000302	CcSEcCtD
Dabrafenib—Leukopenia—Capecitabine—prostate cancer	5.01e-05	0.000302	CcSEcCtD
Dabrafenib—Hypertension—Docetaxel—prostate cancer	4.99e-05	0.000301	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—prostate cancer	4.99e-05	0.000301	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—prostate cancer	4.99e-05	0.000301	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—prostate cancer	4.99e-05	0.000301	CcSEcCtD
Dabrafenib—Erythema—Prednisone—prostate cancer	4.99e-05	0.000301	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—prostate cancer	4.94e-05	0.000298	CcSEcCtD
Dabrafenib—Arthralgia—Docetaxel—prostate cancer	4.92e-05	0.000297	CcSEcCtD
Dabrafenib—Myalgia—Docetaxel—prostate cancer	4.92e-05	0.000297	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—prostate cancer	4.91e-05	0.000296	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Etoposide—prostate cancer	4.9e-05	0.000296	CcSEcCtD
Dabrafenib—Asthenia—Mitoxantrone—prostate cancer	4.9e-05	0.000295	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—prostate cancer	4.9e-05	0.000295	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	4.89e-05	0.000295	CcSEcCtD
Dabrafenib—Cough—Capecitabine—prostate cancer	4.89e-05	0.000295	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—prostate cancer	4.87e-05	0.000293	CcSEcCtD
Dabrafenib—Constipation—Etoposide—prostate cancer	4.86e-05	0.000293	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—prostate cancer	4.85e-05	0.000292	CcSEcCtD
Dabrafenib—Dizziness—Estradiol—prostate cancer	4.85e-05	0.000292	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—prostate cancer	4.84e-05	0.000292	CcSEcCtD
Dabrafenib—Hypertension—Capecitabine—prostate cancer	4.84e-05	0.000291	CcSEcCtD
Dabrafenib—Dry mouth—Docetaxel—prostate cancer	4.82e-05	0.00029	CcSEcCtD
Dabrafenib—Arthralgia—Capecitabine—prostate cancer	4.77e-05	0.000287	CcSEcCtD
Dabrafenib—Myalgia—Capecitabine—prostate cancer	4.77e-05	0.000287	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—prostate cancer	4.76e-05	0.000287	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	4.74e-05	0.000285	CcSEcCtD
Dabrafenib—Oedema—Docetaxel—prostate cancer	4.72e-05	0.000285	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—prostate cancer	4.71e-05	0.000284	CcSEcCtD
Dabrafenib—Vision blurred—Prednisone—prostate cancer	4.7e-05	0.000283	CcSEcCtD
Dabrafenib—Infection—Docetaxel—prostate cancer	4.69e-05	0.000283	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—prostate cancer	4.67e-05	0.000282	CcSEcCtD
Dabrafenib—Diarrhoea—Mitoxantrone—prostate cancer	4.67e-05	0.000282	CcSEcCtD
Dabrafenib—Dry mouth—Capecitabine—prostate cancer	4.66e-05	0.000281	CcSEcCtD
Dabrafenib—Vomiting—Estradiol—prostate cancer	4.66e-05	0.000281	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—prostate cancer	4.65e-05	0.00028	CcSEcCtD
Dabrafenib—Nervous system disorder—Docetaxel—prostate cancer	4.63e-05	0.000279	CcSEcCtD
Dabrafenib—Thrombocytopenia—Docetaxel—prostate cancer	4.62e-05	0.000279	CcSEcCtD
Dabrafenib—Rash—Estradiol—prostate cancer	4.62e-05	0.000279	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—prostate cancer	4.62e-05	0.000278	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—prostate cancer	4.62e-05	0.000278	CcSEcCtD
Dabrafenib—Dermatitis—Estradiol—prostate cancer	4.62e-05	0.000278	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—prostate cancer	4.61e-05	0.000278	CcSEcCtD
Dabrafenib—Headache—Estradiol—prostate cancer	4.59e-05	0.000277	CcSEcCtD
Dabrafenib—Skin disorder—Docetaxel—prostate cancer	4.59e-05	0.000276	CcSEcCtD
Dabrafenib—Oedema—Capecitabine—prostate cancer	4.57e-05	0.000275	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—prostate cancer	4.54e-05	0.000274	CcSEcCtD
Dabrafenib—Infection—Capecitabine—prostate cancer	4.54e-05	0.000274	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—prostate cancer	4.5e-05	0.000271	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—prostate cancer	4.5e-05	0.000271	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—prostate cancer	4.49e-05	0.000271	CcSEcCtD
Dabrafenib—Body temperature increased—Etoposide—prostate cancer	4.49e-05	0.000271	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—prostate cancer	4.49e-05	0.000271	CcSEcCtD
Dabrafenib—Nervous system disorder—Capecitabine—prostate cancer	4.48e-05	0.00027	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—prostate cancer	4.48e-05	0.00027	CcSEcCtD
Dabrafenib—Thrombocytopenia—Capecitabine—prostate cancer	4.48e-05	0.00027	CcSEcCtD
Dabrafenib—Skin disorder—Capecitabine—prostate cancer	4.44e-05	0.000268	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—prostate cancer	4.43e-05	0.000267	CcSEcCtD
Dabrafenib—Hyperhidrosis—Capecitabine—prostate cancer	4.42e-05	0.000266	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—prostate cancer	4.42e-05	0.000266	CcSEcCtD
Dabrafenib—Hypotension—Docetaxel—prostate cancer	4.41e-05	0.000266	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—prostate cancer	4.4e-05	0.000265	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—prostate cancer	4.4e-05	0.000265	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—prostate cancer	4.39e-05	0.000265	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—prostate cancer	4.36e-05	0.000263	CcSEcCtD
Dabrafenib—Nausea—Estradiol—prostate cancer	4.35e-05	0.000262	CcSEcCtD
Dabrafenib—Vomiting—Mitoxantrone—prostate cancer	4.34e-05	0.000262	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—prostate cancer	4.31e-05	0.00026	CcSEcCtD
Dabrafenib—Rash—Mitoxantrone—prostate cancer	4.31e-05	0.00026	CcSEcCtD
Dabrafenib—Dermatitis—Mitoxantrone—prostate cancer	4.3e-05	0.000259	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.3e-05	0.000259	CcSEcCtD
Dabrafenib—Headache—Mitoxantrone—prostate cancer	4.28e-05	0.000258	CcSEcCtD
Dabrafenib—Hypotension—Capecitabine—prostate cancer	4.27e-05	0.000257	CcSEcCtD
Dabrafenib—Insomnia—Docetaxel—prostate cancer	4.27e-05	0.000257	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—prostate cancer	4.25e-05	0.000256	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—prostate cancer	4.25e-05	0.000256	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.22e-05	0.000254	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—prostate cancer	4.19e-05	0.000252	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—prostate cancer	4.19e-05	0.000252	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—prostate cancer	4.17e-05	0.000251	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.16e-05	0.000251	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—prostate cancer	4.15e-05	0.00025	CcSEcCtD
Dabrafenib—Insomnia—Capecitabine—prostate cancer	4.13e-05	0.000249	CcSEcCtD
Dabrafenib—Decreased appetite—Docetaxel—prostate cancer	4.1e-05	0.000247	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—prostate cancer	4.1e-05	0.000247	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—prostate cancer	4.09e-05	0.000246	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Docetaxel—prostate cancer	4.08e-05	0.000246	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—prostate cancer	4.08e-05	0.000246	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—prostate cancer	4.08e-05	0.000246	CcSEcCtD
Dabrafenib—Oedema—Prednisone—prostate cancer	4.07e-05	0.000245	CcSEcCtD
Dabrafenib—Fatigue—Docetaxel—prostate cancer	4.07e-05	0.000245	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—prostate cancer	4.07e-05	0.000245	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—prostate cancer	4.07e-05	0.000245	CcSEcCtD
Dabrafenib—Nausea—Mitoxantrone—prostate cancer	4.06e-05	0.000244	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—prostate cancer	4.05e-05	0.000244	CcSEcCtD
Dabrafenib—Infection—Prednisone—prostate cancer	4.04e-05	0.000244	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—prostate cancer	4.04e-05	0.000243	CcSEcCtD
Dabrafenib—Constipation—Docetaxel—prostate cancer	4.04e-05	0.000243	CcSEcCtD
Dabrafenib—Chills—Epirubicin—prostate cancer	4.02e-05	0.000242	CcSEcCtD
Dabrafenib—Pruritus—Etoposide—prostate cancer	4.02e-05	0.000242	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—prostate cancer	4e-05	0.000241	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—prostate cancer	3.99e-05	0.000241	CcSEcCtD
Dabrafenib—Decreased appetite—Capecitabine—prostate cancer	3.97e-05	0.000239	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—prostate cancer	3.96e-05	0.000239	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—prostate cancer	3.95e-05	0.000238	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Capecitabine—prostate cancer	3.95e-05	0.000238	CcSEcCtD
Dabrafenib—Fatigue—Capecitabine—prostate cancer	3.94e-05	0.000237	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—prostate cancer	3.94e-05	0.000237	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—prostate cancer	3.93e-05	0.000237	CcSEcCtD
Dabrafenib—Constipation—Capecitabine—prostate cancer	3.91e-05	0.000236	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—prostate cancer	3.9e-05	0.000235	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—prostate cancer	3.9e-05	0.000235	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—prostate cancer	3.89e-05	0.000234	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—prostate cancer	3.88e-05	0.000234	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Docetaxel—prostate cancer	3.86e-05	0.000233	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—prostate cancer	3.77e-05	0.000227	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—prostate cancer	3.76e-05	0.000227	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—prostate cancer	3.76e-05	0.000226	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—prostate cancer	3.75e-05	0.000226	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—prostate cancer	3.75e-05	0.000226	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Capecitabine—prostate cancer	3.74e-05	0.000225	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—prostate cancer	3.74e-05	0.000225	CcSEcCtD
Dabrafenib—Abdominal pain—Docetaxel—prostate cancer	3.73e-05	0.000225	CcSEcCtD
Dabrafenib—Body temperature increased—Docetaxel—prostate cancer	3.73e-05	0.000225	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—prostate cancer	3.72e-05	0.000224	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—prostate cancer	3.71e-05	0.000224	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—prostate cancer	3.7e-05	0.000223	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—prostate cancer	3.68e-05	0.000222	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—prostate cancer	3.68e-05	0.000222	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—prostate cancer	3.66e-05	0.000221	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—prostate cancer	3.63e-05	0.000219	CcSEcCtD
Dabrafenib—Abdominal pain—Capecitabine—prostate cancer	3.61e-05	0.000218	CcSEcCtD
Dabrafenib—Body temperature increased—Capecitabine—prostate cancer	3.61e-05	0.000218	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—prostate cancer	3.61e-05	0.000218	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—prostate cancer	3.61e-05	0.000218	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—prostate cancer	3.61e-05	0.000218	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—prostate cancer	3.61e-05	0.000217	CcSEcCtD
Dabrafenib—Rash—Etoposide—prostate cancer	3.58e-05	0.000216	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—prostate cancer	3.58e-05	0.000216	CcSEcCtD
Dabrafenib—Headache—Etoposide—prostate cancer	3.56e-05	0.000214	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—prostate cancer	3.54e-05	0.000213	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—prostate cancer	3.51e-05	0.000212	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—prostate cancer	3.49e-05	0.00021	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—prostate cancer	3.49e-05	0.00021	CcSEcCtD
Dabrafenib—Constipation—Prednisone—prostate cancer	3.48e-05	0.00021	CcSEcCtD
Dabrafenib—Hypersensitivity—Docetaxel—prostate cancer	3.48e-05	0.00021	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—prostate cancer	3.47e-05	0.000209	CcSEcCtD
Dabrafenib—Cough—Epirubicin—prostate cancer	3.4e-05	0.000205	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—prostate cancer	3.4e-05	0.000205	CcSEcCtD
Dabrafenib—Asthenia—Docetaxel—prostate cancer	3.39e-05	0.000204	CcSEcCtD
Dabrafenib—Nausea—Etoposide—prostate cancer	3.37e-05	0.000203	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—prostate cancer	3.37e-05	0.000203	CcSEcCtD
Dabrafenib—Hypersensitivity—Capecitabine—prostate cancer	3.37e-05	0.000203	CcSEcCtD
Dabrafenib—Pruritus—Docetaxel—prostate cancer	3.34e-05	0.000201	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—prostate cancer	3.34e-05	0.000201	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—prostate cancer	3.33e-05	0.000201	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—prostate cancer	3.32e-05	0.0002	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—prostate cancer	3.32e-05	0.0002	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.3e-05	0.000199	CcSEcCtD
Dabrafenib—Asthenia—Capecitabine—prostate cancer	3.28e-05	0.000198	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—prostate cancer	3.25e-05	0.000196	CcSEcCtD
Dabrafenib—Pruritus—Capecitabine—prostate cancer	3.23e-05	0.000195	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—prostate cancer	3.23e-05	0.000195	CcSEcCtD
Dabrafenib—Diarrhoea—Docetaxel—prostate cancer	3.23e-05	0.000195	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—prostate cancer	3.22e-05	0.000194	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—prostate cancer	3.22e-05	0.000194	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—prostate cancer	3.18e-05	0.000192	CcSEcCtD
Dabrafenib—Infection—Epirubicin—prostate cancer	3.16e-05	0.000191	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—prostate cancer	3.15e-05	0.00019	CcSEcCtD
Dabrafenib—Diarrhoea—Capecitabine—prostate cancer	3.13e-05	0.000188	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—prostate cancer	3.12e-05	0.000188	CcSEcCtD
Dabrafenib—Dizziness—Docetaxel—prostate cancer	3.12e-05	0.000188	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—prostate cancer	3.12e-05	0.000188	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—prostate cancer	3.12e-05	0.000188	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—prostate cancer	3.09e-05	0.000186	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—prostate cancer	3.08e-05	0.000186	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—prostate cancer	3.07e-05	0.000185	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—prostate cancer	3.07e-05	0.000185	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.05e-05	0.000184	CcSEcCtD
Dabrafenib—Dizziness—Capecitabine—prostate cancer	3.02e-05	0.000182	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—prostate cancer	3.01e-05	0.000181	CcSEcCtD
Dabrafenib—Vomiting—Docetaxel—prostate cancer	3e-05	0.000181	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisone—prostate cancer	3e-05	0.000181	CcSEcCtD
Dabrafenib—Rash—Docetaxel—prostate cancer	2.98e-05	0.000179	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—prostate cancer	2.98e-05	0.000179	CcSEcCtD
Dabrafenib—Dermatitis—Docetaxel—prostate cancer	2.97e-05	0.000179	CcSEcCtD
Dabrafenib—Headache—Docetaxel—prostate cancer	2.96e-05	0.000178	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—prostate cancer	2.95e-05	0.000178	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—prostate cancer	2.93e-05	0.000176	CcSEcCtD
Dabrafenib—Asthenia—Prednisone—prostate cancer	2.92e-05	0.000176	CcSEcCtD
Dabrafenib—Vomiting—Capecitabine—prostate cancer	2.91e-05	0.000175	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.9e-05	0.000175	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—prostate cancer	2.89e-05	0.000174	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—prostate cancer	2.88e-05	0.000174	CcSEcCtD
Dabrafenib—Rash—Capecitabine—prostate cancer	2.88e-05	0.000174	CcSEcCtD
Dabrafenib—Pruritus—Prednisone—prostate cancer	2.88e-05	0.000174	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—prostate cancer	2.88e-05	0.000174	CcSEcCtD
Dabrafenib—Dermatitis—Capecitabine—prostate cancer	2.88e-05	0.000174	CcSEcCtD
Dabrafenib—Headache—Capecitabine—prostate cancer	2.86e-05	0.000173	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—prostate cancer	2.86e-05	0.000172	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—prostate cancer	2.85e-05	0.000172	CcSEcCtD
Dabrafenib—Nausea—Docetaxel—prostate cancer	2.8e-05	0.000169	CcSEcCtD
Dabrafenib—Diarrhoea—Prednisone—prostate cancer	2.79e-05	0.000168	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—prostate cancer	2.77e-05	0.000167	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—prostate cancer	2.75e-05	0.000166	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—prostate cancer	2.75e-05	0.000166	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—prostate cancer	2.75e-05	0.000165	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—prostate cancer	2.72e-05	0.000164	CcSEcCtD
Dabrafenib—Nausea—Capecitabine—prostate cancer	2.71e-05	0.000164	CcSEcCtD
Dabrafenib—Dizziness—Prednisone—prostate cancer	2.69e-05	0.000162	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.68e-05	0.000162	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—prostate cancer	2.66e-05	0.000161	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—prostate cancer	2.6e-05	0.000157	CcSEcCtD
Dabrafenib—Vomiting—Prednisone—prostate cancer	2.59e-05	0.000156	CcSEcCtD
Dabrafenib—Rash—Prednisone—prostate cancer	2.57e-05	0.000155	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—prostate cancer	2.56e-05	0.000155	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—prostate cancer	2.56e-05	0.000154	CcSEcCtD
Dabrafenib—Headache—Prednisone—prostate cancer	2.55e-05	0.000154	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.54e-05	0.000153	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—prostate cancer	2.54e-05	0.000153	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—prostate cancer	2.52e-05	0.000152	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—prostate cancer	2.52e-05	0.000152	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—prostate cancer	2.52e-05	0.000152	CcSEcCtD
Dabrafenib—Nausea—Prednisone—prostate cancer	2.42e-05	0.000146	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—prostate cancer	2.41e-05	0.000145	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—prostate cancer	2.35e-05	0.000141	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—prostate cancer	2.33e-05	0.00014	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—prostate cancer	2.33e-05	0.00014	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—prostate cancer	2.28e-05	0.000138	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—prostate cancer	2.25e-05	0.000136	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—prostate cancer	2.18e-05	0.000131	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—prostate cancer	2.17e-05	0.000131	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—prostate cancer	2.11e-05	0.000127	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—prostate cancer	2.11e-05	0.000127	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—prostate cancer	2.08e-05	0.000126	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—prostate cancer	2.02e-05	0.000122	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—prostate cancer	2.02e-05	0.000121	CcSEcCtD
Dabrafenib—Rash—Epirubicin—prostate cancer	2.01e-05	0.000121	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—prostate cancer	2.01e-05	0.000121	CcSEcCtD
Dabrafenib—Headache—Epirubicin—prostate cancer	1.99e-05	0.00012	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—prostate cancer	1.95e-05	0.000117	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—prostate cancer	1.89e-05	0.000114	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—prostate cancer	1.87e-05	0.000113	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—prostate cancer	1.86e-05	0.000112	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—prostate cancer	1.86e-05	0.000112	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—prostate cancer	1.85e-05	0.000111	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—prostate cancer	1.75e-05	0.000105	CcSEcCtD
Dabrafenib—RAF1—Innate Immune System—IL6—prostate cancer	2.3e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CAV1—prostate cancer	2.29e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CB—prostate cancer	2.29e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1B1—prostate cancer	2.28e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—prostate cancer	2.27e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—prostate cancer	2.27e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—prostate cancer	2.27e-06	1.63e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NCOA2—prostate cancer	2.25e-06	1.62e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—INS—prostate cancer	2.23e-06	1.61e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—prostate cancer	2.22e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSD3B1—prostate cancer	2.22e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC22A3—prostate cancer	2.22e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—EP300—prostate cancer	2.21e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—prostate cancer	2.21e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GGT1—prostate cancer	2.21e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—prostate cancer	2.2e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—prostate cancer	2.19e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CREBBP—prostate cancer	2.18e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—prostate cancer	2.18e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NCOA1—prostate cancer	2.17e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—prostate cancer	2.17e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BAD—prostate cancer	2.16e-06	1.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—prostate cancer	2.15e-06	1.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—prostate cancer	2.15e-06	1.55e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC5A5—prostate cancer	2.14e-06	1.55e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP19A1—prostate cancer	2.14e-06	1.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—prostate cancer	2.14e-06	1.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TBXAS1—prostate cancer	2.13e-06	1.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA4—prostate cancer	2.13e-06	1.54e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—prostate cancer	2.13e-06	1.54e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—prostate cancer	2.13e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—prostate cancer	2.12e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2E1—prostate cancer	2.09e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—prostate cancer	2.09e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—prostate cancer	2.09e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA2—prostate cancer	2.08e-06	1.5e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—prostate cancer	2.07e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NQO1—prostate cancer	2.07e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—prostate cancer	2.07e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—RXRA—prostate cancer	2.07e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGF—prostate cancer	2.07e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IRS1—prostate cancer	2.07e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—INS—prostate cancer	2.06e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—prostate cancer	2.05e-06	1.48e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SULT1A1—prostate cancer	2.05e-06	1.48e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCG5—prostate cancer	2.05e-06	1.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EP300—prostate cancer	2.04e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TH—prostate cancer	2.04e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—prostate cancer	2.03e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—prostate cancer	2.03e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CREBBP—prostate cancer	2.02e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP3A4—prostate cancer	2.02e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—prostate cancer	2.01e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—prostate cancer	2.01e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.01e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GSK3B—prostate cancer	2.01e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—prostate cancer	2e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA1—prostate cancer	2e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—prostate cancer	2e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—COMT—prostate cancer	1.99e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1B1—prostate cancer	1.99e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—prostate cancer	1.98e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—prostate cancer	1.98e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—prostate cancer	1.98e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSD3B2—prostate cancer	1.98e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NAT2—prostate cancer	1.98e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTO1—prostate cancer	1.98e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—INS—prostate cancer	1.98e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—prostate cancer	1.98e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—prostate cancer	1.95e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ITPR1—prostate cancer	1.95e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CREBBP—prostate cancer	1.94e-06	1.4e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GGT1—prostate cancer	1.92e-06	1.39e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.92e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—prostate cancer	1.92e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—prostate cancer	1.91e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—prostate cancer	1.91e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EP300—prostate cancer	1.91e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—prostate cancer	1.9e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLCB2—prostate cancer	1.9e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2C18—prostate cancer	1.9e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LRP2—prostate cancer	1.9e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NCOA1—prostate cancer	1.89e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EP300—prostate cancer	1.88e-06	1.36e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP19A1—prostate cancer	1.87e-06	1.35e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—P4HB—prostate cancer	1.86e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—prostate cancer	1.85e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAP2K1—prostate cancer	1.85e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMS—prostate cancer	1.84e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—prostate cancer	1.84e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—prostate cancer	1.83e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—prostate cancer	1.82e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SERPINE1—prostate cancer	1.82e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.81e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—prostate cancer	1.81e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—prostate cancer	1.81e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—prostate cancer	1.8e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—RXRA—prostate cancer	1.8e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—prostate cancer	1.8e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—prostate cancer	1.79e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LPL—prostate cancer	1.79e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—prostate cancer	1.79e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—prostate cancer	1.78e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—prostate cancer	1.77e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.76e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF2—prostate cancer	1.76e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—prostate cancer	1.74e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MED12—prostate cancer	1.74e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—COMT—prostate cancer	1.74e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—prostate cancer	1.73e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—prostate cancer	1.73e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1A1—prostate cancer	1.73e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNG5—prostate cancer	1.72e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ERCC2—prostate cancer	1.71e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ITPR1—prostate cancer	1.7e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JAK2—prostate cancer	1.69e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—prostate cancer	1.67e-06	1.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—prostate cancer	1.66e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA3—prostate cancer	1.66e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—prostate cancer	1.66e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—prostate cancer	1.66e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—prostate cancer	1.65e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—prostate cancer	1.65e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MDM2—prostate cancer	1.65e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—prostate cancer	1.64e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—prostate cancer	1.64e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—prostate cancer	1.64e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—prostate cancer	1.64e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—prostate cancer	1.63e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—prostate cancer	1.62e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—prostate cancer	1.61e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—prostate cancer	1.61e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMS—prostate cancer	1.61e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—prostate cancer	1.6e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—prostate cancer	1.59e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HPGDS—prostate cancer	1.58e-06	1.14e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARA—prostate cancer	1.58e-06	1.14e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.57e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—prostate cancer	1.56e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LPL—prostate cancer	1.56e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—prostate cancer	1.54e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—prostate cancer	1.54e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—prostate cancer	1.54e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACHE—prostate cancer	1.54e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.52e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—prostate cancer	1.52e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—prostate cancer	1.51e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1A1—prostate cancer	1.5e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—prostate cancer	1.5e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ERCC2—prostate cancer	1.49e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—EP300—prostate cancer	1.49e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAV1—prostate cancer	1.49e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.48e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PRKACB—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—prostate cancer	1.46e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.45e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—prostate cancer	1.44e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—prostate cancer	1.43e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—prostate cancer	1.42e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.42e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—prostate cancer	1.41e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—prostate cancer	1.4e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—prostate cancer	1.39e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—prostate cancer	1.39e-06	1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—prostate cancer	1.39e-06	1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA2—prostate cancer	1.38e-06	9.99e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—prostate cancer	1.38e-06	9.98e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—EP300—prostate cancer	1.38e-06	9.93e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARA—prostate cancer	1.38e-06	9.93e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—prostate cancer	1.36e-06	9.85e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.35e-06	9.76e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—prostate cancer	1.35e-06	9.74e-06	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—prostate cancer	1.34e-06	9.65e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—prostate cancer	1.34e-06	9.64e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.32e-06	9.53e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EP300—prostate cancer	1.32e-06	9.52e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAV1—prostate cancer	1.29e-06	9.33e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.29e-06	9.31e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—prostate cancer	1.28e-06	9.26e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—INS—prostate cancer	1.28e-06	9.24e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NQO1—prostate cancer	1.28e-06	9.2e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TH—prostate cancer	1.26e-06	9.07e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CREBBP—prostate cancer	1.25e-06	9.05e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—prostate cancer	1.25e-06	9.02e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—prostate cancer	1.25e-06	9.01e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—prostate cancer	1.24e-06	8.93e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—prostate cancer	1.23e-06	8.9e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—prostate cancer	1.23e-06	8.9e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.22e-06	8.82e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.19e-06	8.58e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GGT1—prostate cancer	1.18e-06	8.55e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—prostate cancer	1.18e-06	8.5e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA1—prostate cancer	1.17e-06	8.42e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—prostate cancer	1.15e-06	8.31e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.15e-06	8.3e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—prostate cancer	1.15e-06	8.3e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—prostate cancer	1.15e-06	8.28e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—prostate cancer	1.14e-06	8.22e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—prostate cancer	1.12e-06	8.11e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—prostate cancer	1.12e-06	8.1e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—INS—prostate cancer	1.12e-06	8.05e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—RXRA—prostate cancer	1.11e-06	8.01e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—prostate cancer	1.1e-06	7.93e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CREBBP—prostate cancer	1.09e-06	7.88e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—COMT—prostate cancer	1.07e-06	7.71e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—prostate cancer	1.06e-06	7.68e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—prostate cancer	1.06e-06	7.66e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ITPR1—prostate cancer	1.05e-06	7.55e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.04e-06	7.48e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—prostate cancer	1.04e-06	7.47e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—prostate cancer	1.03e-06	7.41e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—prostate cancer	1.02e-06	7.35e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMS—prostate cancer	9.89e-07	7.14e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—prostate cancer	9.78e-07	7.06e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—prostate cancer	9.78e-07	7.05e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—prostate cancer	9.76e-07	7.04e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPL—prostate cancer	9.6e-07	6.92e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—prostate cancer	9.44e-07	6.81e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1A1—prostate cancer	9.27e-07	6.69e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ERCC2—prostate cancer	9.19e-07	6.63e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—prostate cancer	9.03e-07	6.51e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—prostate cancer	8.98e-07	6.48e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—prostate cancer	8.96e-07	6.46e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—prostate cancer	8.95e-07	6.46e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—prostate cancer	8.64e-07	6.24e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—prostate cancer	8.64e-07	6.23e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—EP300—prostate cancer	8.54e-07	6.16e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARA—prostate cancer	8.48e-07	6.12e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—prostate cancer	8.32e-07	6e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—prostate cancer	7.97e-07	5.75e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAV1—prostate cancer	7.97e-07	5.75e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—prostate cancer	7.8e-07	5.63e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—EP300—prostate cancer	7.44e-07	5.37e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—prostate cancer	7.26e-07	5.24e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—INS—prostate cancer	6.87e-07	4.96e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CREBBP—prostate cancer	6.73e-07	4.86e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—prostate cancer	6.38e-07	4.61e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—prostate cancer	6.32e-07	4.56e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—prostate cancer	6.03e-07	4.35e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—prostate cancer	5.56e-07	4.01e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—prostate cancer	5.51e-07	3.98e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—prostate cancer	5.51e-07	3.97e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—prostate cancer	5.16e-07	3.72e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—prostate cancer	4.81e-07	3.47e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—EP300—prostate cancer	4.59e-07	3.31e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—prostate cancer	4.5e-07	3.24e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.39e-07	2.45e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—prostate cancer	2.77e-07	2e-06	CbGpPWpGaD
